Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for Iradimed (IRMD) over the last 7 years, with Q3 2025 value amounting to $12.7 million.

  • Iradimed's Shares Outstanding (Weighted Average) rose 40.31% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 40.31%. This contributed to the annual value of $12.7 million for FY2024, which is 53.37% up from last year.
  • Iradimed's Shares Outstanding (Weighted Average) amounted to $12.7 million in Q3 2025, which was up 40.31% from $12.7 million recorded in Q2 2025.
  • Iradimed's Shares Outstanding (Weighted Average)'s 5-year high stood at $12.7 million during Q3 2025, with a 5-year trough of $12.3 million in Q2 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $12.6 million (2023), whereas its average is $12.6 million.
  • As far as peak fluctuations go, Iradimed's Shares Outstanding (Weighted Average) soared by 200.79% in 2022, and later increased by 28.04% in 2023.
  • Quarter analysis of 5 years shows Iradimed's Shares Outstanding (Weighted Average) stood at $12.3 million in 2021, then rose by 1.76% to $12.6 million in 2022, then rose by 0.32% to $12.6 million in 2023, then rose by 0.53% to $12.7 million in 2024, then grew by 0.4% to $12.7 million in 2025.
  • Its last three reported values are $12.7 million in Q3 2025, $12.7 million for Q2 2025, and $12.7 million during Q1 2025.